Gleiss Lutz advised the Japanese chemicals and pharmaceuticals company Daicel Corporation on the acquisition of 100 per cent of the shares in the Lomapharm Group. The seller is the Luxembourg-based private equity investor Lenbach Equity Opportunities I. SCSp. The parties have agreed not to disclose the purchase price. Closing of the transaction is still subject to the customary regulatory clearances.
Established in 1919, Daicel Corporation operates in the chemical and medical sector. Its core technologies include cellulose derivatives, organic chemicals and polymers as well as pre-mix excipients. The company, headquartered in Osaka, has around 12,000 employees in 14 countries and is listed on the Tokyo Stock Exchange. The transaction will enable Daicel to enter the pharmaceutical formulation business as well as to expand its excipients business.
Lomapharm is an independent, mid-sized pharmaceutical company specialising in the manufacture of medicinal products and food supplements as well as medical devices. With more than 135 qualified and experienced employees, the company produces solid, liquid and sterile dosage forms. Its strengths include the development and galenic optimisation of pharmaceutical formulations and the manufacture of sugar-coated and film-coated tablets.
Headed by Dr. Michael Burian (lead, partner), Dr. Martin Lembke (counsel) and Alexandra Brücher (all corporate/M&A, all Stuttgart), the Gleiss Lutz team comprised: Dr. Martin Viciano Gofferje (partner, corporate/M&A, Berlin), Dr. Jens Günther (partner), Dr. Eva Heup (both employment, Munich), Dr. Matthias Sonntag (partner), Dr. Benedikt Burger (both IP, Düsseldorf), Dr. Petra Linsmeier (partner), Dr. Iris Benedikt-Buckenleib (counsel), Tobias Klemm (all competition/antitrust, Munich), Dr. Fabian Kutz (real estate), Patrick Reuter (finance, both Frankfurt), Dr. Johann Wagner (partner), Dr. Jens Wrede, Dr. Thomas Bücheler (all tax, Hamburg), Dr. Enno Burk (healthcare, Berlin), Dr. Marc Ruttloff (counsel, Stuttgart) and Dr. Lars Kindler (Berlin, both public law).
Gleiss Lutz has a leading Japan practice which frequently advises Japanese companies on acquisitions in Germany: most recently, Nippon Life on a cornerstone investment and strategic alliance as part of the IPO of DWS as well as the Japanese electronics group JVCKenwood on the acquisition of Rein Medical, a manufacturer and developer of software and hardware solutions for the medical IT sector.